TG Therapeutics, Inc.
NASDAQ:TGTXBiotechnology
+$1.03 today
- Market cap
- $9.99B
- Beta
- 1.68
- P/E (TTM)
- 16.4
- EPS (TTM)
- $3.20
Volume 1.87M
Average 2.15M
TGTX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
TG Therapeutics, Inc.NASDAQ: TGTX
EPS (Diluted) · Q3 FY2026 · quarter ended Sep 2026
EPS (Diluted) declines year over year
Q3 FY2026 EPS (Diluted) of $0.35 fell 85.6% year over year, behind the -76.3% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 600.0% from the prior quarter.
Context
- EPS (Diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of $1.03 (-62.7%) for the fiscal year ending Dec 2026, a slowdown from the +1746.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $0.35+600.0% QoQ
- Last fiscal yearDec 2025
- $2.77+1746.7% YoY
- LTMSep 2026
- $0.66-76.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -85.6% | +236.7% | +322.3 pp |
| 1 year | +1746.7% | -62.7% | -1809.3 pp |
| 3-year CAGR | — | +10.2% | — |
| 5-year CAGR | +12.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 2.77 USD
- Year-over-year change
- +1746.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.77 | +1746.7% |
| FY2024 | 2024-12-31 | 0.15 | +75.8% |
| FY2023 | 2023-12-31 | 0.09 | +105.8% |
| FY2022 | 2022-12-31 | (1.46) | +44.5% |
| FY2021 | 2021-12-31 | (2.63) | — |
EPS (Diluted) vs competitors
How TGTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -76.3% is the lowest of 7, against a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $1.27 USD | — | -42.9% | |
| LTM Sep 2026 | $0.66 USD | -76.3% | — | |
| FY2025 | -€0.53 EUR | +13.1% | — | |
| LTM Mar 2026 | -$0.55 USD | +43.9% | — | |
| LTM Jun 2024 | -$0.9 USD | — | — | |
| LTM Mar 2026 | -$1.05 USD | +27.4% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| LTM Jun 2026 | -$2.17 USD | +13.5% | — | |
| LTM Sep 2026 | -$4.31 USD | -27.5% | — | |
| Peer median (excluding TGTX) | — | +13.3% | -42.9% | |
Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.69M | 2.79M | 233.66M | 329M | 616.29M |
| Cost of Revenue | 790K | 265K | 14.13M | 38.49M | 100.71M |
| Gross Profit | 5.9M | 2.52M | 219.53M | 290.52M | 515.57M |
| Gross Margin | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% |
| Research & Development | 222.58M | 125.35M | 76.19M | 94.29M | 160.22M |
| Selling, General & Admin | 128.09M | 95.48M | 122.71M | 154.3M | 232.03M |
| Operating Expenses | 350.67M | 220.84M | 198.9M | 248.59M | 392.25M |
| Depreciation & Amortization | 494K | 515K | 423K | 280K | 244K |
| EBITDA | (341.97M) | (213.11M) | 26.1M | 49.9M | 134.36M |
| EBITDA Margin | -5112.4% | -7651.9% | 11.2% | 15.2% | 21.8% |
| Operating Income | (344.77M) | (218.32M) | 20.63M | 41.93M | 123.32M |
| Operating Margin | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.64M | 10.19M | 12.62M | 24.03M | 26.73M |
| Other Income / Expenses | (3.33M) | (5.5M) | (7.57M) | (16.34M) | (15.93M) |
| Income Before Tax | (348.1M) | (223.81M) | 13.06M | 25.59M | 107.39M |
| Pre-Tax Margin | -5204.1% | -8036.3% | 5.6% | 7.8% | 17.4% |
| Income Tax Expense | 0 | 0 | 390K | 2.21M | (339.79M) |
| Net Income | (348.1M) | (223.81M) | 12.67M | 23.38M | 447.18M |
| Net Margin | -5204.1% | -8036.3% | 5.4% | 7.1% | 72.6% |
| EPS (Basic) | (2.63) | (1.46) | 0.09 | 0.16 | 3.10 |
| EPS (Diluted) | (2.63) | (1.46) | 0.09 | 0.15 | 2.77 |
| Weighted Avg Shares | 132.22M | 135.41M | 141.96M | 145.32M | 144.32M |
| Weighted Avg Shares (Diluted) | 132.22M | 135.41M | 148.51M | 160.34M | 161.41M |
TG Therapeutics, Inc.
NASDAQ:TGTX
Intrinsic Alpha fair value
Locked
Current Price
$66.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.